Pomerantz LLP Opens Securities Fraud Investigation Into Integra LifeSciences After Two Stock Plunges

Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holding Corporation for potential securities fraud, the firm said in a PR Newswire release dated November 12, 2026. The investigation concerns whether Integra and certain of its officers or directors engaged in securities fraud or other unlawful business practices.

Pomerantz's Integra LifeSciences Investigation

Pomerantz LLP is a plaintiff-side securities litigation law firm founded in 1936 that represents investors in securities class actions, corporate governance cases and global investor recovery proceedings, according to akta.pro company records. The firm advises Integra investors to contact Danielle Peyton at 646-581-9980, ext. 7980.

The investigation follows two stock drops. On October 2, 2026, Integra LifeSciences pre-announced disappointing operational performance and cut its full-year 2026 revenue guidance range by $30.5 million at the midpoint. The company said severe flooding at its Cincinnati facility in July 2026 caused widespread operational disruptions, impacting third-quarter revenues by roughly $7 million and creating an anticipated $15 million to $20 million headwind for the fourth quarter. Integra's stock price fell $3.41 per share, or 21.2%, to close at $12.68 per share on October 2, 2026.

On October 21, 2026, Integra released its finalized third-quarter 2026 financial results, confirming a revenue miss of $411.2 million against internal and analyst expectations. The company admitted that the Cincinnati facility disruption was worse than originally anticipated and disclosed that execution pressure and competitive headwind constraints had driven an organic revenue contraction of 2.2% within its critical Tissue Reconstruction segment. Integra's stock price fell $1.17 per share, or 8.76%, to close at $12.16 per share on October 21, 2026.

Integra's Conference Remarks on Demand

At the 2026 UBS Global Healthcare Conference, Integra LifeSciences CFO Lea Knight discussed stable procedure volumes in neurosurgery and tissue reconstruction, citing durable demand and clinical evidence, Seeking Alpha reported. Investing.com reported that Integra cited specialty surgery growth of 4% and neurosurgery up 6.5% at the conference, with free cash flow projected to rise to $130–140 million in 2025.

Pomerantz's Recent Investor Cases

Pomerantz LLP announced on August 25, 2026 that a class action lawsuit had been filed against GPGI, Inc., alleging securities fraud or unlawful business practices by the company and certain officers or directors, FinancialContent Business Page reported. On August 21, 2026, Pomerantz filed a class action lawsuit against Aardvark Therapeutics and its officers for alleged securities fraud related to the company's IPO and subsequent clinical trial data, FinancialContent Business Page reported. On August 11, 2026, Pomerantz announced an investigation into Yum! Brands on behalf of investors concerning potential securities fraud related to a cyclosporiasis outbreak at Taco Bell restaurants in Michigan that resulted in two deaths, FinancialContent Business Page reported.

What to Watch Next

Pomerantz LLP's proposed class action settlement for purchasers of Gritstone bio securities has a hearing set for December 4, 2026, with claims due by November 13, 2026, PR Newswire reported.